Goldman Sachs
KYNB

Goldman Sachs’s Kyntra Bio KYNB Stock Holding History

Goldman Sachs’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,288
Closed -$9.98K – 6182
2025
Q1 		$9.98K Sell
1,288
-524
-29% -$6.28K ﹤0.01% 5970
2024
Q4 		$24K Sell
1,812
-251
-12% -$2.33K ﹤0.01% 5886
2024
Q3 		$20.6K Sell
2,063
-41,597
-95% -$628K ﹤0.01% 5671
2024
Q2 		$974K Buy
43,660
+39,613
+979% +$1.22M ﹤0.01% 4434
2024
Q1 		$238K Sell
4,047
-5,015
-55% -$216K ﹤0.01% 5058
2023
Q4 		$201K Sell
9,062
-7,230
-44% -$109K ﹤0.01% 5152
2023
Q3 		$351K Sell
16,292
-19,258
-54% -$756K ﹤0.01% 4821
2023
Q2 		$2.4M Buy
35,550
+13,241
+59% +$5.48M ﹤0.01% 3720
2023
Q1 		$10.4M Buy
22,309
+4,578
+26% +$2.42M ﹤0.01% 2378
2022
Q4 		$7.1M Sell
17,731
-7,371
-29% -$2.82M ﹤0.01% 2873
2022
Q3 		$8.16M Sell
25,102
-4,360
-15% -$1.4M ﹤0.01% 2693
2022
Q2 		$7.78M Buy
29,462
+2,419
+9% +$618K ﹤0.01% 2742
2022
Q1 		$8.13M Sell
27,043
-13,344
-33% -$4.65M ﹤0.01% 2900
2021
Q4 		$14.2M Buy
40,387
+4,266
+12% +$1.33M ﹤0.01% 2437
2021
Q3 		$9.23M Buy
36,121
+5,659
+19% +$2.01M ﹤0.01% 2807
2021
Q2 		$20.3M Sell
30,462
-5,689
-16% -$3.28M ﹤0.01% 2040
2021
Q1 		$31.4M Sell
36,151
-4,097
-10% -$4.36M 0.01% 1549
2020
Q4 		$37.3M Buy
40,248
+1,405
+4% +$1.48M 0.01% 1348
2020
Q3 		$39.9M Sell
38,843
-4,868
-11% -$5.24M 0.01% 1171
2020
Q2 		$44.3M Buy
43,711
+855
+2% +$794K 0.01% 1046
2020
Q1 		$37.2M Buy
42,856
+918
+2% +$913K 0.01% 1070
2019
Q4 		$45M Buy
41,938
+6,981
+20% +$7.13M 0.01% 1224
2019
Q3 		$32.3M Buy
34,957
+7,894
+29% +$8.67M 0.01% 1422
2019
Q2 		$30.6M Sell
27,063
-3,789
-12% -$4.15M 0.01% 1520
2019
Q1 		$41.9M Buy
30,852
+569
+2% +$772K 0.01% 1273
2018
Q4 		$35M Buy
30,283
+9,931
+49% +$11.2M 0.01% 1364
2018
Q3 		$30.9M Sell
20,352
-9,434
-32% -$14.5M 0.01% 1590
2018
Q2 		$46.6M Buy
29,786
+2,946
+11% +$3.84M 0.01% 1258
2018
Q1 		$31M Buy
26,840
+6,485
+32% +$8.54M 0.01% 1502
2017
Q4 		$24.1M Sell
20,355
-6,181
-23% -$7.75M 0.01% 1790
2017
Q3 		$35.7M Buy
26,536
+10,001
+60% +$10.5M 0.01% 1525
2017
Q2 		$13.4M Buy
16,535
+4,504
+37% +$3.14M ﹤0.01% 2282
2017
Q1 		$7.42M Buy
12,031
+3,764
+46% +$2.29M ﹤0.01% 2614
2016
Q4 		$4.42M Buy
8,267
+2,695
+48% +$1.35M ﹤0.01% 3155
2016
Q3 		$2.88M Sell
5,572
-27,256
-83% -$12.8M ﹤0.01% 3512
2016
Q2 		$13.5M Buy
32,828
+1,541
+5% +$706K ﹤0.01% 2091
2016
Q1 		$16.7M Buy
31,287
+16,367
+110% +$8.16M 0.01% 1854
2015
Q4 		$11.4M Buy
14,920
+312
+2% +$207K ﹤0.01% 2158
2015
Q3 		$8.01M Buy
14,608
+7,838
+116% +$4.75M ﹤0.01% 2437
2015
Q2 		$3.98M Sell
6,770
-13,618
-67% -$7.92M ﹤0.01% 3167
2015
Q1 		$16M Buy
20,388
+1,216
+6% +$943K 0.01% 1922
2014
Q4 		$13.1M Buy
+19,172
New +$12.3M ﹤0.01% 2137

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's KYNB Position: Q2 2025 in Review

Goldman Sachs sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 1,288 shares — an estimated $9.98K sold.

Goldman Sachs first reported a position in KYNB in Q4 2014 and held it in 42 quarters. The position peaked at $46.6M in Q2 2018. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Goldman Sachs reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,288 Kyntra Bio shares in Q2 2025, an estimated $9.98K.
  • Goldman Sachs first reported a position in Kyntra Bio in Q4 2014 and held it in 42 quarters.
  • Goldman Sachs's Kyntra Bio position peaked at $46.6M in Q2 2018.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.